Clinical Director, Breast Oncology Program Stuart B. Padnos Professor of Breast Cancer Research University of Michigan Ann Arbor, Michigan
The North American Breast Cancer Group (NABCG) and the Breast International Group (BIG) have prospectively collected and stored breast cancer tissues, blood, serum and DNA from patients who participated in clinical trials for correlative science studies of new or promising tumor biomarkers. Since 2006, BCRF has supplied support for ongoing correlative science activities of the NABCG and BIG, including support for approved studies, for infrastructure projects related to archived specimens, and collaborations between the two groups. At least 18 papers and reports at major scientific meetings have been published by investigators funded by BCRF. Inventories of the archived tissues are now publically available, and these specimens have been centrally evaluated for the major breast cancer biomarkers: ER, PgR, and HER2. Major workshops have led to initiatives within the NABCG for pharmacogenomics studies, to standardize assays for an important biomarker, Ki67, and to plan correlative sciences for one of the NABCG major trials, TAILORx . Further, BCRF funding has been used to conduct world-wide efforts to standardize analysis of Ki67, a major biomarker that is often used to guide adjuvant chemotherapy. In the coming year, the NABCG will continue to provide support to investigators whose concepts are approved by the NABCG Correlative Sciences Committee and to BIG to further support their translational science activities.
Daniel Hayes, MD, is the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center (UMCCC) and the Stuart B. Padnos Professor of Breast Cancer Research. He received AB (1974) and MS (1977) degrees at Indiana University, his MD from the Indiana University School of Medicine (1979), a residency in Internal Medicine at the UTHSC, Dallas, Texas (Parkland Memorial Hospital, 1979-1982), and a fellowship in Medical Oncology at Harvard’s Dana Farber Cancer Institute (DFCI, 1982–1985). From 1992–1996, he was Medical Director of the Breast Evaluation Center at DFCI. In 1996, he moved to the Georgetown University Lombardi Cancer Center, and he joined the UMCCC in 2001. Dr. Hayes has a national and international reputation in the field of experimental therapeutics targeted to breast cancer, working on serum and tissue markers such as HER-2, circulating tumor cells and pharmacogenomics which have prognostic and/or predictive value in the treatment of breast cancer. In June 2015 he became president-elect of the American Society of Clinical Oncology.